CN112534506B - 组织特异性的甲基化标志物 - Google Patents

组织特异性的甲基化标志物 Download PDF

Info

Publication number
CN112534506B
CN112534506B CN201980032333.3A CN201980032333A CN112534506B CN 112534506 B CN112534506 B CN 112534506B CN 201980032333 A CN201980032333 A CN 201980032333A CN 112534506 B CN112534506 B CN 112534506B
Authority
CN
China
Prior art keywords
target sequence
methylation
cancer
tissue
readable medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980032333.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN112534506A (zh
Inventor
卢煜明
赵慧君
陈君赐
盖万霞
姬露
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grail Inc
Original Assignee
Grail Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grail Inc filed Critical Grail Inc
Priority to CN202510148128.0A priority Critical patent/CN119955906A/zh
Publication of CN112534506A publication Critical patent/CN112534506A/zh
Application granted granted Critical
Publication of CN112534506B publication Critical patent/CN112534506B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C12Q1/6823—Release of bound markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/20—Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201980032333.3A 2018-03-15 2019-03-15 组织特异性的甲基化标志物 Active CN112534506B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510148128.0A CN119955906A (zh) 2018-03-15 2019-03-15 组织特异性的甲基化标志物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862643649P 2018-03-15 2018-03-15
US62/643,649 2018-03-15
US201862769928P 2018-11-20 2018-11-20
US62/769,928 2018-11-20
PCT/US2019/022504 WO2019178496A1 (en) 2018-03-15 2019-03-15 Tissue-specific methylation marker

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510148128.0A Division CN119955906A (zh) 2018-03-15 2019-03-15 组织特异性的甲基化标志物

Publications (2)

Publication Number Publication Date
CN112534506A CN112534506A (zh) 2021-03-19
CN112534506B true CN112534506B (zh) 2025-03-04

Family

ID=67908065

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980032333.3A Active CN112534506B (zh) 2018-03-15 2019-03-15 组织特异性的甲基化标志物
CN202510148128.0A Pending CN119955906A (zh) 2018-03-15 2019-03-15 组织特异性的甲基化标志物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510148128.0A Pending CN119955906A (zh) 2018-03-15 2019-03-15 组织特异性的甲基化标志物

Country Status (11)

Country Link
US (2) US11884966B2 (https=)
EP (1) EP3766076A4 (https=)
JP (2) JP7620803B2 (https=)
CN (2) CN112534506B (https=)
AU (1) AU2019233897B2 (https=)
CA (1) CA3093971A1 (https=)
IL (1) IL277306A (https=)
PH (1) PH12020551712A1 (https=)
SG (1) SG11202008957VA (https=)
TW (1) TWI848941B (https=)
WO (1) WO2019178496A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7620803B2 (ja) 2018-03-15 2025-01-24 グレイル インコーポレイテッド 組織特異的メチル化マーカー
KR102155044B1 (ko) * 2019-10-08 2020-09-11 주식회사 레피다인 생물학적 시료의 간암 조직 기원 여부를 판별하는 방법
KR102103885B1 (ko) * 2019-10-08 2020-04-24 주식회사 레피다인 생물학적 시료의 간 조직 유래 여부를 판별하는 방법
JP2023516525A (ja) * 2019-12-26 2023-04-20 広州市基准医療有限公司 Ｄｎａメチル化バイオマーカーの組み合わせ、検出方法および試薬キット
GB2612447B (en) * 2020-04-24 2025-08-13 Univ Cornell Methods for detecting tissue damage, graft versus host disease, and infections using cell-free DNA profiling
EP4291677A2 (en) 2021-02-09 2023-12-20 F. Hoffmann-La Roche AG Methods for base-level detection of methylation in nucleic acids
WO2023144704A1 (en) * 2022-01-25 2023-08-03 Gene Solutions Joint Stock Company Systems and methods for detecting tumor dna in mammalian blood
EP4540408A1 (en) 2022-06-14 2025-04-23 F. Hoffmann-La Roche AG Detection of epigenetic cytosine modification
WO2024112741A1 (en) * 2022-11-23 2024-05-30 Salk Institute For Biological Studies Dna methylation barcodes for identifying brain cells
CN117476222B (zh) * 2023-09-28 2024-10-25 上海交通大学医学院附属瑞金医院 一种肠癌肝转移的风险预测方法、系统和电子设备

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014043763A1 (en) * 2012-09-20 2014-03-27 The Chinese University Of Hong Kong Non-invasive determination of methylome of fetus or tumor from plasma

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX349568B (es) 2010-11-30 2017-08-03 Univ Hong Kong Chinese Deteccion de aberraciones geneticas o moleculares asociadas con el cancer.
US9732390B2 (en) * 2012-09-20 2017-08-15 The Chinese University Of Hong Kong Non-invasive determination of methylome of fetus or tumor from plasma
CN106232833A (zh) 2014-01-30 2016-12-14 加利福尼亚大学董事会 用于非侵入性诊断的甲基化单体型分析(monod)
EP3132055A2 (en) * 2014-04-14 2017-02-22 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. A method and kit for determining the tissue or cell origin of dna
WO2015169947A1 (en) 2014-05-09 2015-11-12 Lifecodexx Ag Detection of dna that originates from a specific cell-type and related methods
EP2942400A1 (en) * 2014-05-09 2015-11-11 Lifecodexx AG Multiplex detection of DNA that originates from a specific cell-type
JP6722659B2 (ja) 2014-06-04 2020-07-15 クエスト ダイアグノスティクス インベストメンツ インコーポレイテッド 結腸直腸癌のためのメチル化マーカー
ES2741400T3 (es) 2014-07-18 2020-02-10 Univ Hong Kong Chinese Análisis de patrones de metilación de tejidos en mezcla de ADN
ES2879964T3 (es) * 2014-12-12 2021-11-23 Exact Sciences Dev Co Llc Composiciones y métodos para realizar ensayos de detección de metilación
CN109312404A (zh) 2016-01-29 2019-02-05 表观基因组股份有限公司 用于检测血液样品中肿瘤来源DNA的CpG甲基化的方法
JP2019521673A (ja) 2016-06-07 2019-08-08 ザ リージェンツ オブ ザ ユニヴァーシティー オブ カリフォルニア 疾患および状態の分析のためのセルフリーｄｎａメチル化パターン
JP7620803B2 (ja) 2018-03-15 2025-01-24 グレイル インコーポレイテッド 組織特異的メチル化マーカー

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014043763A1 (en) * 2012-09-20 2014-03-27 The Chinese University Of Hong Kong Non-invasive determination of methylome of fetus or tumor from plasma

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Epigenetic alteration: new insights moving from tissue to plasma – the example of PCDH10 promoter methylation in colorectal cancer;E Danese;British Journal of Cancer;20130709;第109卷;参见第810页右栏第1至第812页左栏最后1段 *
Liver-and Colon-Specific DNA Methylation Markers in Plasma for Investigation of Colorectal Cancers with or without Liver Metastases;Wanxia Gai;Clinical Chemistry;第64卷(第8期);第1239-1249页 *

Also Published As

Publication number Publication date
IL277306A (en) 2020-10-29
JP2024156679A (ja) 2024-11-06
WO2019178496A1 (en) 2019-09-19
CA3093971A1 (en) 2019-09-19
SG11202008957VA (en) 2020-10-29
TWI848941B (zh) 2024-07-21
EP3766076A1 (en) 2021-01-20
KR20210023804A (ko) 2021-03-04
EP3766076A4 (en) 2021-12-29
US20190390257A1 (en) 2019-12-26
JP2021518107A (ja) 2021-08-02
AU2019233897A1 (en) 2020-10-22
US20240191282A1 (en) 2024-06-13
TW202010845A (zh) 2020-03-16
CN119955906A (zh) 2025-05-09
AU2019233897B2 (en) 2024-10-24
JP7620803B2 (ja) 2025-01-24
PH12020551712A1 (en) 2021-06-21
CN112534506A (zh) 2021-03-19
US11884966B2 (en) 2024-01-30

Similar Documents

Publication Publication Date Title
CN112534506B (zh) 组织特异性的甲基化标志物
JP7022188B2 (ja) 無細胞核酸の多重解像度分析のための方法
CN112752854B (zh) 用于通过肿瘤分数和覆盖率调整肿瘤突变负荷的方法和系统
ES2991960T3 (es) Identificación del origen somático o germinal del ADN libre de células
JP2022050571A (ja) 発現レベルおよび配列変種情報を用いて疾患の発症または再発のリスクを評価するための方法
CN112930569B (zh) 无细胞dna中的微卫星不稳定性检测
JP2023514851A (ja) 癌の病態を判別または示すメチル化パターンの同定
CN116583904A (zh) 用于癌症分类的样品确认
JP2024535886A (ja) ノイズ性領域フィルタ除去を有するメチル化フラグメント確率ノイズモデル
WO2023226938A1 (zh) 甲基化生物标记物、试剂盒及用途
AU2024210217A1 (en) Methods and systems for detecting and assessing liver conditions
KR102954537B1 (ko) 조직 특이적 메틸화 마커
HK40042779A (en) Tissue-specific methylation marker
HK40042779B (zh) 组织特异性的甲基化标志物
US20250226108A1 (en) Multi-tiered testing for tracking cancer heterogeneity
WO2025179073A1 (en) Methods and systems for tissue informed differentially methylated region analysis
WO2026015665A1 (en) Determining methylation status of biological samples
CN115667544A (zh) 鉴定染色体外dna特征的方法
Beggs et al. The future structure of care: cancer genetics

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40042779

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant